IL2 and systemic lupus erythematosus: Clinical trials across various autoimmune diseases, such as SLE, RA, type 1 diabetes, and Primary Sjögren's Syndrome, have demonstrated that Low-dose IL-2 can safely and effectively induce stable Treg cell proliferation and restore immune balance, leading to improved disease activity (266–271).